paclitaxel

 Switching CDK4/6i and ET conferred a statistically significant improvement of PFS in patients with progression or recurrence on prior CDK4/6i-containing therapy. These findings underscore the variability in survival outcomes based on post-CDK4/6i therapy choices in HR+/HER2- MBC, with promising evidence for rechallenging strategies.

Follow-up imaging during treatment showed marked reduction of the pericardial and pleural effusions, with improvement in arthralgia and activities of daily living. Although the benefit was transient, this case suggests that systemic chemotherapy in combination with bevacizumab may have contributed not only to temporary effusion control in advanced PEH but also to relief of PEH-associated HPOA, while concomitant zoledronic acid may also have supported symptom improvement.

This case demonstrates a rare gastric metastasis in bilateral ILC in addition to a diagnostic challenge of differentiating orbital metastasis from pseudotumor.

Transcriptomic analysis also confirmed enrichment of immune-related pathways. In summary, the combined therapy mediated by the PTX/R848 stent achieves comprehensive and effective treatment of malignant tracheal stenosis and related metastases.

Phenotype-specific therapies are incorporated through simple pharmacodynamic surrogates: Paclitaxel chemotherapy acting primarily on HER2+ cells and Notch-pathway inhibition targeting HER2- cells...In contrast, simultaneous initiation suppresses both phenotypes more effectively and avoids strong rebound. These findings highlight the importance of ecological structure in therapy design and support simultaneous combination therapy followed by targeted maintenance.

P2, N=70, Recruiting, Innate Pharma | Trial completion date: Sep 2026 --> Jun 2027 | Trial primary completion date: Jun 2025 --> Jun 2027

P4, N=100, Not yet recruiting, GlaxoSmithKline

A 62-year-old man with metastatic PSA underwent splenectomy followed by first-line paclitaxel, achieving stable disease for 7 months...Sequential treatment with liposomal doxorubicin, eribulin, toripalimab, and lenvatinib failed to control the disease failed to control the disease...To our knowledge, this is the first reported use of inavolisib in angiosarcoma. The rapid biochemical and radiological response observed in this PIK3CA-mutated PSA supports early genomic profiling to identify actionable alterations and warrants prospective evaluation of combined phosphoinositide 3-kinase and vascular endothelial growth factor pathway inhibition in refractory angiosarcoma.

Selenium treatment significantly mitigated these adverse effects in a dose-dependent manner by restoring endocrine balance, enhancing antioxidant defense, suppressing inflammatory and apoptotic pathways, and improving spermatogenesis. Collectively, these findings demonstrate that selenium exerts a protective role against PTX-induced reproductive toxicity by modulating key chemical-biological interaction pathways involved in testicular injury.

Scanning electron microscopy, immunofluorescence, Western Blot, and other molecular functional assays show that the ERRα/LDHA axis drives lactate accumulation, downregulates inflammasome-related proteins (NLRP3, caspase-1, GSDMD and GSDMD-N), thereby suppressing pyroptosis and promoting resistance to cisplatin, carboplatin, and paclitaxel in ovarian cancer cells. Created in BioRender. Ren, Y. (2025) https://BioRender.com/qeh0dw8.

P4, N=50, Recruiting, University of Wisconsin, Madison | Trial completion date: Jun 2026 --> Jun 2027 | Trial primary completion date: Jun 2026 --> Jun 2027

Furthermore, fenofibrate exhibits synergistic effects with conventional chemotherapeutic agents (e.g., paclitaxel and docetaxel) by enhancing T-cell viability, activating immune responses, and thereby improving chemotherapy sensitivity. This review comprehensively summarizes the efficacy and underlying mechanisms of fenofibrate against diverse cancer types and discusses the potential applications and challenges associated with its repurposing for cancer therapy. A deeper understanding of fenofibrate's anti-cancer capabilities and molecular targets may provide novel insights for the development of innovative therapeutic strategies.